Suppr超能文献

细胞周期蛋白依赖性激酶7在健康与疾病中的新作用

Emerging roles of cyclin-dependent kinase 7 in health and diseases.

作者信息

Belew Mahder Dawit, Chen Jingrui, Cheng Zhaokang

机构信息

Department of Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd., Spokane, WA 99202-2131, USA.

Department of Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd., Spokane, WA 99202-2131, USA.

出版信息

Trends Mol Med. 2025 Feb;31(2):138-151. doi: 10.1016/j.molmed.2024.09.004. Epub 2024 Oct 15.

Abstract

Cyclin-dependent kinase 7 (CDK7) regulates cell cycle and transcription, which are central for cancer progression. CDK7 inhibitors exhibit substantial anticancer activities in preclinical studies and are currently being evaluated in clinical trials. CDK7 is widely expressed in the body. However, the impact of CDK7 inhibition on normal tissues has received little attention. Here, we review the biological functions of CDK7, followed by its emerging roles in development, homeostasis and diseases. We discuss the regulatory mechanisms of CDK7 kinase activation and provide an overview of CDK7 substrates identified to date. Moreover, we highlight unanswered questions and propose key areas for future investigation. An advanced understanding of CDK7 will facilitate the pharmaceutical development of CDK7 inhibitors and help minimize undesirable adverse effects.

摘要

细胞周期蛋白依赖性激酶7(CDK7)调节细胞周期和转录,这对癌症进展至关重要。CDK7抑制剂在临床前研究中显示出显著的抗癌活性,目前正在临床试验中进行评估。CDK7在体内广泛表达。然而,CDK7抑制对正常组织的影响很少受到关注。在此,我们综述了CDK7的生物学功能,随后阐述其在发育、体内平衡和疾病中的新作用。我们讨论了CDK7激酶激活的调控机制,并概述了迄今为止已确定的CDK7底物。此外,我们强调了尚未解决的问题,并提出了未来研究的关键领域。对CDK7的深入了解将有助于CDK7抑制剂的药物研发,并有助于将不良副作用降至最低。

相似文献

1
Emerging roles of cyclin-dependent kinase 7 in health and diseases.
Trends Mol Med. 2025 Feb;31(2):138-151. doi: 10.1016/j.molmed.2024.09.004. Epub 2024 Oct 15.
2
Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Future Med Chem. 2020 May;12(9):813-833. doi: 10.4155/fmc-2019-0334. Epub 2020 Mar 25.
3
CDK7 inhibitors as anticancer drugs.
Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8.
4
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
J Med Chem. 2020 Jul 23;63(14):7458-7474. doi: 10.1021/acs.jmedchem.9b01985. Epub 2020 Mar 19.
6
Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Expert Opin Investig Drugs. 2021 Jan;30(1):61-76. doi: 10.1080/13543784.2021.1850693. Epub 2021 Jan 11.
7
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Expert Opin Ther Pat. 2023 Feb;33(2):67-87. doi: 10.1080/13543776.2023.2195547. Epub 2023 Apr 10.
10
Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Transcription. 2019 Apr;10(2):47-56. doi: 10.1080/21541264.2018.1553483. Epub 2018 Dec 6.

引用本文的文献

本文引用的文献

1
Structural basis of Cdk7 activation by dual T-loop phosphorylation.
Nat Commun. 2024 Aug 3;15(1):6597. doi: 10.1038/s41467-024-50891-z.
2
CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release.
Mol Cell. 2024 Jun 20;84(12):2287-2303.e10. doi: 10.1016/j.molcel.2024.05.007. Epub 2024 May 30.
5
Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition.
Mol Cell. 2023 Nov 16;83(22):4078-4092.e6. doi: 10.1016/j.molcel.2023.10.017.
6
Distinctive interactomes of RNA polymerase II phosphorylation during different stages of transcription.
iScience. 2023 Aug 9;26(9):107581. doi: 10.1016/j.isci.2023.107581. eCollection 2023 Sep 15.
10
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Blood. 2023 Jun 8;141(23):2841-2852. doi: 10.1182/blood.2022018885.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验